Regulatory Approval

With its acquisition of French startup QPerfect, BTQ isn't just buying software; it's buying a strategic R&D hub and a powerful emulation-first approach.

Oklo's Texas reactor just cleared a major safety hurdle. It's more than a win for one company; it's a test of a new, faster model for U.S. nuclear deployment.

The FDA approved Orca Bio's revolutionary cell therapy, promising better outcomes for cancer patients. But the real test lies beyond the science.

The FDA's approval of a potent new triglyceride drug comes with a staggering price tag, forcing a showdown with an established, affordable therapy.

A small NJ town sells its water system for $6.4M to tackle aging pipes and PFAS. What does this mean for residents and the future of public utilities?

Health Canada has greenlit drones for pesticide application, unlocking a new era of precision agriculture and positioning Canada in the global ag-tech race.

The FDA now allows ZYN to be marketed as lower-risk than cigarettes, a landmark win for harm reduction. But critics fear it opens a new door to nicotine addiction.

A key USCIS approval for a Detroit-area project reveals how the EB-5 investor visa program is channeling foreign funds into American job creation.

Once a quiet niche, the wAIHA market is now a battleground for J&J, Sanofi, and Novartis, with a 14.4% growth forecast and a new class of drugs.

Sarepta seeks full FDA approval for two Duchenne drugs, leaning on real-world evidence after a key trial missed its goal. A test case for rare disease innovation.

Thirty women have received a revolutionary absorbable scaffold that uses their own fat to regenerate breast tissue, promising an end to implant-related risks.

A legislative tour of Anfield Energy’s Velvet-Wood uranium mine highlights a controversial new playbook for boosting U.S. energy security through accelerated permitting.

Saluda Medical secures FDA approval for its CAP24™ paddle lead, expanding its advanced closed-loop neuromodulation to surgeons and chronic pain patients.

Webull Canada's new CIRO-approved crypto trading offers mainstream access, but a closer look reveals the unmitigated risks lurking beneath the regulatory sheen.

With stringent NYS approval secured, Fellow Health’s mail-in semen analysis enters a key market, signaling a major shift in at-home diagnostics and male reproductive care.

Luxembourg's STOKR gains rare CASP and PI licenses, setting a new standard for institutional tokenization as many rivals face EU market suspension.

New data on at-home lecanemab injections signals a major shift in Alzheimer's care, promising greater convenience and access for patients and caregivers.

With FDA Priority Review for its at-home therapy Enspryng, Roche is signaling a major disruption in the lucrative Thyroid Eye Disease market.

EdgeCortix's AI platform just got a major green light from the Pentagon's innovation arm. What does this mean for the future of battlefield tech and space AI?